HomeAdalimumab AatyAdalimumab Aaty + Anakinra

Does Adalimumab Aaty Interact with Anakinra?

Adalimumab Aaty and Anakinra have a major drug interaction according to U.S. FDA drug labeling data. Increased risk of serious infection with no added benefit. Concomitant use not recommended in patients with RA. The mechanism involves tnf blocker combined with biologic dmard increases infection risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Anakinra Class
Interleukin-1 Receptor Antagonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Adalimumab Aaty and Anakinra occurs because tnf blocker combined with biologic dmard increases infection risk. Clinically, this means increased risk of serious infection with no added benefit. concomitant use not recommended in patients with ra. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Adalimumab Aaty and your doctor is considering prescribing Anakinra (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Adalimumab Aaty(Adalimumab)+💊 Anakinra(Kineret)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Interleukin-1 Receptor Antagonist
Source
NLP:adalimumab-aaty

What this means in plain English

Increased risk of serious infection with no added benefit. Concomitant use not recommended in patients with RA.

What the FDA label says

"TNF blocker combined with biologic DMARD increases infection risk"

📖 Source: NLP:adalimumab-aaty

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Adalimumab Aaty and Anakinra against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.